Welcome to our dedicated page for XRTXF news (Ticker: XRTXF), a resource for investors and traders seeking the latest updates and insights on XRTXF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XRTXF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XRTXF's position in the market.
XORTX Therapeutics announced the successful closing of a public offering on October 15, 2021, raising approximately US$12 million through the sale of 2,906,000 units, each consisting of one common share and one warrant with an exercise price of US$4.77. The offering has positioned the company for strategic advancement in its clinical programs, particularly for products targeting progressive kidney disease. The company also granted underwriters a 45-day option for additional shares, enhancing liquidity.
XORTX Therapeutics Inc. will participate in the LD Micro Main Event from October 12-14, 2021. The company, focused on innovative therapies for progressive kidney disease, emphasizes the importance of this conference for connecting with investors and analysts. CEO Allen Davidoff mentioned the significance of investor presentations, while LD Micro founder Chris Lahiji expressed excitement about returning to in-person events. The company's products target conditions like Autosomal Dominant Polycystic Kidney Disease and COVID-19. A replay will be available on their website.
XORTX Therapeutics Inc. has announced a public offering of 2,906,000 units at a price of US$4.13 each, aimed at raising approximately US$12 million in gross proceeds. Each unit comprises one common share and one warrant with an exercise price of US$4.77. The offering has received conditional approval to list on the Nasdaq under the symbol 'XRTX.' The offering is expected to close around October 15, 2021. Additionally, the company has granted underwriters a 45-day option to purchase additional shares. XORTX focuses on developing therapies for progressive kidney disease.
XORTX Therapeutics Inc. (CSE:XRX, OTCQB:XRTXF) has announced its participation in the virtual LD Micro investor conference on March 18, 2021. Dr. Allen Davidoff, the company's President and CEO, expressed excitement about presenting to a diverse group of investors, highlighting the significant work the team has accomplished. The conference aims to address the unmet medical needs associated with ADPKD, a disease that affects many. XORTX is developing therapies targeting progressive kidney disease, including products for COVID-19 and Type 2 Diabetic Nephropathy.
XORTX Therapeutics (CSE:XRX, OTCQB:XRTXF) is participating in the Sachs 14th Annual European Life Sciences CEO Forum on March 10-11, 2021. This virtual conference focuses on the challenges and developments in the bio-pharma sector. Dr. Allen Davidoff, CEO, emphasized the event's role in enhancing exposure for the company's innovative kidney disease therapies. XORTX is advancing several clinical programs, including treatments for Autosomal Dominant Polycystic Kidney Disease and Type 2 Diabetic Nephropathy, utilizing proprietary uric acid-lowering formulations.
XORTX Therapeutics (CSE:XRX, OTCQB:XRTXF) announced the filing of a new provisional patent on March 5, 2021, titled "Compositions and Methods for Enhancing Anti-Viral Therapies." This patent addresses the enhanced risk of acute kidney injury and other complications in COVID-19 patients. Dr. Allen Davidoff highlighted that the patent leverages data suggesting a therapeutic opportunity in addressing purine metabolism and hyperuricemia in high-risk patients. XORTX aims to develop therapies targeting kidney disease and related complications from viral infections.
XORTX Therapeutics (XRTXF) is participating in the BIO CEO and Investor Digital Conference from February 16-18, 2021. CEO Dr. Allen Davidoff will present the company's innovative kidney disease programs, including XRx-008 for ADPKD and XRx-101 for AKI linked to COVID-19. The presentation aims to highlight XORTX's commitment to addressing unmet needs in kidney disease treatment. The conference facilitates networking within the biotech industry, enhancing visibility among investors and partners.
